I agree J8. They aren't in a hurry as they've got a plan in place and they are acting on that plan. No deal until phase 2 data I recall them stating. I guess Cochlear CEO summed it up this week in commenting on their very lovely profit result - for investors in the R&D game to be patient as it's a long cycle. If Benny is the next Cochlear and that includes waiting for Phase 2 results then i'm prepared and sitting in.
There's no risk we're well placed as holders in this tech, and the Sanofi/Voyager deal just reiterates this. Voyager still need to perform to get their near $1B etc. This deal puts pressure on other big pharma watching the space and increases Benitec's bargaining power, no doubt about that. Data first, big pharma signing second, share price at a 89% gradient immediately after that, with settling at something more like one of those US equivalents.
- Forums
- ASX - By Stock
- BLT
- Sanofi Signs Benitec's closest competitor Voyager for $845M
Sanofi Signs Benitec's closest competitor Voyager for $845M, page-30
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add BLT (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online